Regeneron Pharmaceuticals, Inc. (REGN)

Biotech plants and research, 78% in the U.S. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 4, 2026. Ranked 82 of the 95 Healthcare companies read so far, by the share within reach now.

The filing counts 15,410 full-time employees with 6,717 in industrial operations and 4,865 in research and clinical development, 11,961 of them in the United States.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 18% now, 36% at the end of 2027, 46% at the end of 2028, 51% at the end of 2030. By the patterns, the work is about 51% desk work, 15% people work and 34% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 49% of the working time stays with people (conversation, in-person and hands-on work), 41% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

15,410 employees as of December 31, 2025 (stated). 11,961 of 15,410 full-time employees in the United States (78%), 2,149 in Ireland and 1,300 elsewhere, stated.

The filing: “As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries (primarily in the United Kingdom, Japan, and Germany).”

The workforce as industry patterns

What the filing says about the workforce: 15,410 full-time; 2,591 in research and preclinical development, 2,274 in clinical development and regulatory affairs, 6,717 in industrial operations and product supply; over 1,800 hold a Ph.D. or M.D.; independent contractors, contingent and temporary workers supplement the workforce, outside the count (rule 8); works councils outside the U.S.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

7 sentences in the filing name AI. Seven sentences: the company says it is increasingly using artificial intelligence-based solutions across its operations and exploring further uses, and a risk factor names the inherent risks of that use beside trade secret and data security risks.

• “Our ability to protect our trade secrets may be impaired by a number of risks and uncertainties, including those discussed under "Other Regulatory and Litigation Risks - The use of social media platforms could give rise to liability, breaches of data security and privacy laws, or reputational damage ," "Other Regulatory and Litigation Risks - There are inherent risks related to our increasing u...”
• “There are inherent risks related to our increasing use of artificial intelligence-based solutions.”
• “We are increasingly utilizing artificial intelligence ("AI")-based solutions in various facets of our operations and continue to explore further use cases for AI.”
• “The use of AI solutions by our employees or third parties on which we rely may lead to the impermissible use or public disclosure of sensitive data.”
• “In the United States and in many jurisdictions outside the United States, new regulations have recently passed or have been proposed to ensure the ethical use, privacy, and security of AI solutions and the data processed thereby.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20236median 1
• Fiscal 20247median 4
• Fiscal 20257median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The research and development organizations are counted (a) and read apart from the plants; earlier pharmaceutical readings whose filings counted no research staff carry one pattern.

Source: the company's annual report on EDGAR, accession 0000872589-26-000008, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.